文献速递其他结缔组织病

人血管类器官再现系统性硬化症从血管病变向纤维化转变的关键机制

Human blood vessel organoids recapitulate key mechanisms of transition from vasculopathy to fibrosis in systemic sclerosis.
PubMed 文献 · Ann Rheum Dis · 2026-03-22

本研究利用诱导多能干细胞来源的血管类器官(BVO)构建系统性硬化症(SSc)血管病变的多细胞人源模型,发现SSc来源BVO暴露于SSc血清后出现血管完整性降低、内皮-周细胞交互丧失及内皮间质转化(EndMT),且SSc IgG可重现该病理表型,波生坦与DAPT可部分逆转血管异常。

要点

  • SSc血清诱导SSc-BVO出现血管生成缺陷、EndMT及纤维化基因上调。
  • SSc IgG缺失可恢复血管结构,向健康血清转移SSc IgG可重现病理表型。
  • 波生坦与γ-分泌酶抑制剂DAPT部分逆转血管异常并下调EndMT标志物。

核心结论

  • BVO可再现SSc血管病变及其向纤维化转变,遗传易感性与致病性自身抗体协同驱动微血管损伤。
  • Notch/γ-分泌酶抑制被提出作为SSc血管病变的潜在新靶点。

研究设计与样本

  • 研究采用SSc患者与健康对照的诱导多能干细胞来源的血管类器官(BVO),并暴露于SSc微血管病变患者血清或健康供者血清。
  • 通过共聚焦成像、RNA测序、ATAC测序和空间蛋白质组学(CODEX)评估结构与分子变化,并选择性去除或富集血清IgG以探究抗体作用。

主要发现

  • SSc来源BVO暴露于SSc血清后出现严重血管生成缺陷,表现为血管完整性降低、内皮-周细胞交互丧失及内皮间质转化(EndMT)诱导。
  • 表观遗传与转录谱显示纤维化相关基因上调及内皮标志物丢失,空间蛋白质组学在蛋白水平证实EndMT并显示内皮与周细胞亚群及其交互改变。
  • 从SSc血清中去除IgG可恢复血管结构,将SSc IgG转移至健康血清可重现病理表型。
  • 波生坦和DAPT均部分逆转血管异常并下调EndMT标志物。

临床怎么用

  • SSc-BVO可作为评估预防血管病变向纤维化转变的治疗药物的平台。
  • Notch/γ-分泌酶抑制(如DAPT)被提出作为SSc血管病变的潜在新靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Systemic sclerosis (SSc) is an autoimmune disease that transitions from vasculopathy as an initiating pathogenic event to tissue fibrosis. The mechanisms of these transitions remain, however, poorly understood, mainly because complex multicellular human models of SSc vasculopathy are lacking. We aimed to develop a complex multicellular human model of SSc vasculopathy and use it to investigate the mechanisms underlying this process. METHODS: Blood vessel organoids (BVOs) were derived from induced pluripotent stem cells of patients with SSc and healthy controls. Organoids were exposed to serum from patients with SSc with clinically manifest microvasculopathy or healthy donors. Structural and molecular changes were evaluated using confocal imaging, transcriptomic (RNA sequencing), epigenetic (assay for transposase-accessible chromatin sequencing), and spatial proteomic (codetection by indexing) profiling. Serum immunoglobulin G (IgG) was selectively depleted or enriched to investigate antibody contributions. Therapeutic interventions included bosentan and the γ-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT). RESULTS: SSc-derived BVOs exposed to SSc serum exhibited profound angiogenic defects, characterised by reduced vessel integrity, loss of endothelial-pericyte interactions, and induction of endothelial-to-mesenchymal transition (EndMT). Epigenetic and transcriptional profiling revealed upregulation of fibrosis-related genes and loss of endothelial markers. Spatial proteomic data confirmed EndMT at the protein level and demonstrated shifts in endothelial and pericyte subpopulation as well as alterations in their interactions reminiscent of those seen in tissues of patient with SSc. IgG depletion from SSc serum restored vascular structure, and transfer of SSc IgG to healthy serum phenocopied the pathological phenotype, implicating autoantibodies in endothelial injury. Both bosentan and DAPT partially reversed vascular abnormalities and downregulated EndMT markers. CONCLUSIONS: This study establishes BVOs as a complex human model of SSc vasculopathy and demonstrates in a multiomic approach that they recapitulate disease-specific vascular dysfunction and its transition to fibrosis. We show that genetic susceptibility and pathogenic autoantibodies synergise in driving microvascular injury in SSc. Furthermore, we provide evidence that SSc BVOs are a promising platform for evaluating therapies that prevent the transition from vasculopathy to fibrosis, and present Notch/γ-secretase inhibition as a potential novel target in SSc vasculopathy.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Xiao Y, Hong X, Zhi L, et al. Human blood vessel organoids recapitulate key mechanisms of transition from vasculopathy to fibrosis in systemic sclerosis. Ann Rheum Dis. 2026. PMID: 41866288. doi:10.1016/j.ard.2026.02.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。